Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes

Keyphrases

• Left Ventricular Hypertrophy 100%
• Type 2 Diabetes Mellitus (T2DM) 100%
• Chronic Kidney Disease 100%
• Finerenone 100%
• Placebo 23%
• Cardiovascular Outcomes 23%
• Heart Failure Hospitalization 23%
• Kidney 17%
• Kidney Outcomes 17%
• Hypertension 11%
• Treatment Effect 11%
• Overall Safety 11%
• Cardiovascular Mortality 5%
• Patient Demographics 5%
• AIMS™ 5%
• Placebo-controlled 5%
• Cardiovascular Risk 5%
• Comorbidity 5%
• Nonfatal Myocardial Infarction 5%
• Efficacy Outcomes 5%
• Hyperkalemia 5%
• Estimated Glomerular Filtration Rate 5%
• Randomized Double-blind 5%
• High Prevalence 5%
• Hospitalization Risk 5%
• Phase II Study 5%
• Safety Outcomes 5%
• Treatment-related Adverse Events 5%
• Nonfatal Stroke 5%
• Treatment Emergent 5%
• Kidney Failure 5%
• Discontinuation Rate 5%
• Mineralocorticoid Receptor Antagonists 5%
• Time to Onset 5%
• Relative Risk Reduction 5%
• Safety Events 5%
• FIDELIO-DKD 5%
• FIGARO 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Comorbidity 5%
• Cardiovascular Disease 5%

Medicine and Dentistry

• Comorbidity 5%